Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Genetically-engineered Preclinical Models Predict Pharmacodynamic… >
Genetically-engineered Preclinical Models Predict Pharmacodynamic Response

Published: September 19, 2012.
By University of North Carolina Health Care
http://www.med.unc.edu

New cancer drugs must be thoroughly tested in preclinical models, often in mice, before they can be offered to cancer patients for the first time in phase I clinical trials. Key components of this process include pharmacokinetic and pharmacodynamic studies, which evaluate how the drug acts on a living organism. These studies measure the pharmacologic response and the duration and magnitude of response observed relative to the concentration of the drug at an active site in the organism.

A new comparison of four different methodologies for pharmacokinetic and pharmacodynamic testing of the anti-melanoma agent carboplatin, demonstrates that genetically-engineered mouse models provide tumor delivery of drug most comparable to the response seen in melanoma patients.

"These studies are critically important in the case of small-molecule cancer drugs, which often have systemic side effects and can be toxic at high concentrations," said Ned Sharpless, MD, Wellcome Distinguished Professor of Cancer Research and study co-author.

The study, led by Bill Zamboni, PharmD and PhD, Associate Professor of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy and a member of UNC Lineberger Comprehensive Cancer Center, and Ned Sharpless, MD, who is also Associate Director for Translational Research at UNC Lineberger.

The collaborative study, which appears in The Oncologist, brought together a set of unique resources available at UNC to determine which preclinical models best predict delivery of carboplatin to melanoma tumors in patients. "We have a unique opportunity to evaluate an important factor in the treatment of solid tumors because of the outstanding collaborative nature and novel resources at UNC", said Zamboni.

"We have used a pharmacokinetics testing method called microdialysis, which uses a tiny probe to take samples that measure serial drug concentrations in a tumor over time," he added. "We plan to use this method to advance pharmacology studies of anticancer agents in tumors and tissues of patients and to evaluate the tumor delivery of nanoparticles and other classes of delivery agents."

The team used the resources of the preclinical phase I unit at UNC Lineberger to compare how pharmacokenetic levels vary in several preclinical tumor models including a genetically-engineered model, a model where tumor cells are transplanted to the appropriate part of the body (called an orthotopic syngeneic transplant or OST), and a xenograft model, where human tumor tissue is transplanted.

"Because carboplatin is widely used, we have good data on how the drug works pharmacokenetically in humans. For the first time, we were able to compare these various laboratory techniques used in countless labs and the pharmaceutical industry to evaluate how carboplatin was delivered to the tumor and compare it to actual human data. None of these laboratory models are perfect, but the genetically-engineered model is the best in terms of predicting the amount of drug that is delivered to the tumor in human patients," Zamboni added.

"We know that laboratory models are imperfectly predictive of human response and if the tumor models don't predict delivery, they are most likely not an optimal research tools," he noted.

Sharpless added, "We are continually looking for ways to build better laboratory models so that new therapies move from the lab to the patient as quickly and safely as possible. This study provides valuable validation that genetically-engineered models can help us accomplish this objective."


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Cancer 
4/12/10 
UNC Study Offers First Clinical Evidence of Anti-cancer Drug Triggering Viral Infection
By University of North Carolina School of Medicine
Chapel Hill, NC - Important advances in the fight against cancer have come as researchers proved that viruses and cancers interact in ways that were previously unknown to scientists. …
Trial 
8/12/13 
Mayo Clinic: Preclinical Tests May Lead to New Approach to Treat CNS Lymphoma
By Mayo Clinic
JACKSONVILLE, Fla. -- A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer …
Sunitinib 
2/7/13 
Reassuring Evidence: Anticancer Drug Does Not Accelerate Tumor Growth After Treatment Ends
By Cell Press
Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the …
Rhabdomyosarcoma 
3/31/11 
OHSU Doernbecher Discovers New Approach to Drug Resistance in Aggressive Childhood Cancer
By Oregon Health & Science University
PORTLAND, Ore. — Researchers at Oregon Health & Science University Doernbecher Children's Hospital have identified a promising new approach to overcoming drug resistance in children with an extremely aggressive …
Survival 
3/19/12 
Hutchinson Center Scientists Break Through Pancreas Cancer Treatment Barrier
By Fred Hutchinson Cancer Research Center
Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition